Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
BCDA | US
-0.11
-10.68%
Healthcare
Biotechnology
30/06/2024
08/06/2026
0.92
1.03
1.05
0.86
BioCardia Inc. a clinical-stage regenerative medicine company engages in development of cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP an autologous mononuclear cell therapy system for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease. The company is also developing allogeneic cells therapeutic platform an investigational culture expanded bone marrow derived mesenchymal cell therapy which is in Phase I/II trial for the treatment of ischemic heart failure. In addition it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart; and Morph deflectable guides and sheaths. The company is based in Sunnyvale California.
View LessLow Debt to Equity (< 0.25)
Price Below SMA10D
High Short-term Volatility
Microcap (<300M USD)
High Market Beta (> 0.8)
Rich in Valuation (Price to Book > 8)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
96.6%1 month
88.5%3 months
59.4%6 months
58.9%-
-
10.67
-0.58
0.39
-3.16
20.90
-
-8.53M
3.22M
3.22M
-
-54.97K
-
-93.00
-703.62
0.22
4.06
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.94
Range1M
0.96
Range3M
0.96
Rel. volume
0.72
Price X volume
5.29M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Ensysce Biosciences Inc | ENSC | Biotechnology | 0.253 | 3.51M | -0.43% | n/a | 24.79% |
| Evogene Ltd | EVGN | Biotechnology | 0.583 | 3.26M | -5.82% | n/a | 26.41% |
| PRFX | PRFX | Drug Manufacturers-Specialty & Generic | 1.46 | 3.25M | -8.18% | n/a | -2.89% |
| Alaunos Therapeutics Inc | TCRT | Biotechnology | 2 | 3.20M | -12.28% | n/a | 0.00% |
| Curis Inc | CRIS | Biotechnology | 0.4701 | 2.81M | -0.68% | n/a | -6039.91% |
| 60 Degrees Pharmaceuticals Inc. Common Stock | SXTP | Biotechnology | 1.43 | 2.66M | 0.70% | n/a | 5.19% |
| BioRestorative Therapies Inc | BRTX | Biotechnology | 0.362 | 2.51M | -10.62% | n/a | 0.77% |
| PALISADE BIO INC | PALI | Biotechnology | 1.74 | 2.41M | 0.00% | n/a | 5.06% |
| Allarity Therapeutics Inc. Common Stock | ALLR | Biotechnology | 1.58 | 2.23M | -1.86% | n/a | 6.68% |
| Hiru Corporation | HIRU | Biotechnology | 0.0011 | 2.08M | 10.00% | n/a | 263.27% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.0058 | 534.84K | n/a | -37.05% | |
| Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 0.4181 | 230.37K | 7.87% | n/a | 0.00% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -3.16 | 0.53 | Cheaper |
| Ent. to Revenue | 20.90 | 3,967.00 | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 10.67 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 59.42 | 72.80 | Par |
| Debt to Equity | -0.58 | -1.23 | Expensive |
| Debt to Assets | 0.39 | 0.25 | Expensive |
| Market Cap | 3.22M | 3.66B | Emerging |